Table 3 The objective response rate(ORR)and the disease control rate (DCR) of patients treated with pemetrexed-based therapy in four groups
From: Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers
HER2 | EGFR | ALK/ROS1 | KRAS | P value | |
|---|---|---|---|---|---|
n | 25 | 74 | 39 | 40 | |
ORR% | 36.0 | 33.8 | 41.3 | 35.0 | 0.896 |
DCR% | 92.0 | 78.4 | 87.2 | 72.5 | 0.139 |